Two drugs used in combination prove to be effective against most aggressive asbestos cancer in mice

January 08, 2020

Exposure to asbestos is the major risk factor for malignant mesothelioma, a type of aggressive cancer that mostly affects the pleura - the tissue that lines the lungs - and the peritoneum - the tissue that lines the abdomen. This has been known for decades, yet the molecular characterisation of mesothelioma is barely known and treatment options are scarce. A study carried out by researchers at the Spanish National Cancer Research Centre (CNIO) on key molecular processes in this type of cancer identified two drugs that, used in combination, could be effective against the most aggressive type of mesothelioma. The compounds are already being used in clinical trials for other tumours, a fact that might help speed up studies on mesothelioma patients.

In addition, the authors of the study suggest a set of molecular markers for predictive therapy response, which can be used to determine which patients are eligible for the clinical trials.

The study, led by Paco Real, Head of the Epithelial Carcinogenesis Group at CNIO, and researcher Miriam Marqués, from the same Group, is being published in Cancer Research.

"The results of the study are relevant because mesothelioma has not been widely studied, has a poor prognosis and no targeted therapies," says Paco Real. "We have found evidence in mice and human cell lines of the potential effectiveness of two compounds that are by no means new. Now we want to start performing clinical trials as soon as possible."

Mesothelioma - a rare form of cancer

In Spain, five out of a million people die of mesothelioma every year. This figure is likely to increase over the next years in the country and at the European level too. Mesothelioma is commonly considered an occupational disease occurring after decades of exposure to asbestos in the workplace. In Spain, asbestos was widely used in the construction industry, especially in the 1960s, until it was banned as a potential health hazard in 2001.

Mesothelioma is a relatively rare form of cancer and, consequently, it is rarely studied in depth. The most aggressive type of mesothelioma is known as sarcomatoid carcinoma and accounts for nearly 25% of cases. Survival times of patients with this type of mesothelioma who get the currently available therapies range between 14 and 18 months.

It is precisely on sarcomatoid mesothelioma that the study carried out by the Epithelial Carcinogenesis Group at CNIO focuses.

Unexpected finding

The results of the study were to a great extent unexpected. The researchers were working on bladder cancer in mice, focusing on two tumour suppressor genes: Pten and Trp53. Surprisingly, the mice did not develop bladder cancer but an aggressive form of sarcomatoid mesothelioma. (The authors believe that, given the fast development of this aggressive form of mesothelioma, there was no time for bladder tumours to develop.)

Looking for the molecular cause of the rapid spread of the tumour cells, the researchers identified enhanced activity of the MEK/ERK and PI3K pathways via novel mechanisms involving a protein of the GPCR family. Blockage of these pathways with MEK and PI3Kbeta inhibitors reduced the proliferative and invasive capacities of mesothelioma cells in mice.

Drug testing under way

The following step consisted of looking for drugs that would inhibit the above-mentioned proteins and that were already being tested in humans. These drugs are Selumetinib, a MEK inhibitor, and AZD8186, a molecule that targets PI3Kbeta.

In Paco Real's words, "First we identified altered molecules in sarcomatoid mesothelioma in mice, then we verified that the proteins were also altered in sarcomatoid mesothelioma in humans and found a drug combo that was effective both in mice and in human cell lines. We chose drugs that were already being tested for other human tumours, because their toxicity is well understood and so they can be used in clinical trials soon."

Since Pten and TP53 are tumour suppressor genes, and MEK and PIK3beta show enhanced activity in many other human tumours, the findings might be relevant to types of cancer other than malignant mesothelioma. Marqués and Real are studying this possibility as well.
The study has been funded by the Spanish Ministry of Science, Innovation and Universities, the National Institute of Health Carlos III, the Spanish Association Against Cancer (AECC), the European Regional Development Fund and the Institut National de la Santé et de la Recherche Médicale (France).

Centro Nacional de Investigaciones Oncológicas (CNIO)

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to